Lantern Pharma LTRN 深 沪
等待开盘 10-15 09:30:00 美东时间
0.673
-0.038
-5.30%
华盛通- 最 高0.7106
- 今 开0.71
- 成交量 21.23万股
- 最 低 0.651
- 昨 收 0.7107
- 总市值 1005.16万
- 52周最高 4.34
- 市盈率 静 --
- 换手率 1.42%
- 52周最低 0.651
- 委 比 -27.54%
- 总股本 1493.56万
- 历史最高 24.84
- 量 比 0.97
- 振 幅 8.39%
- 历史最低 0.651
- 每 手 1
- 风险率 0.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lantern Pharma Showcases Open-Medicine AI Growth Strategy
Lantern Pharma ( ($LTRN) ) has provided an update. On September 23, 2026, Lante...
09-23 20:21
Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers
Lantern Pharma Inc. (NASDAQ:LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No....
09-22 19:46
Lantern Pharma Earnings Call: AI Spinout, Trial Momentum
Lantern Pharma, Inc. (($LTRN)) has held its Q2 earnings call. Read on for the m...
08-25 08:22
Lantern Pharma Forms Open Medicine AI Subsidiary Business
Lantern Pharma ( ($LTRN) ) just unveiled an announcement. Lantern Pharma report...
08-14 19:59
Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.38) by 50 percent. This is a 42.5 percent decrease over losses of $(0.40) per share from the same period last year.
08-14 19:43
Lantern Pharma Creates Open-Medicine AI As Separate Entity
Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which have received Lantern Pharma Board app...
08-03 19:34
Lantern Pharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For 'Methods For The Treatment Of Solid Tumor Cancers Using Illudins And Biomarkers'
The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers." The allowed claims cover methods of selecting and treating patients wi...
07-23 20:09
Lantern Pharma Launches ZetaOmics, A Computational-Biology Module Of Its WithZeta.ai Co-Scientist Platform
ZetaOmics introduces an autonomous "Computational Biologist" persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for the rare and pediatric cancers that have long been underserved by dedicated computational resources an...
07-08 19:33
Lantern Pharma Reports Clinical Data And Updates From Ongoing Phase 2 HARMONIC Trial Evaluating LP-300 In Combination With Carboplatin And Pemetrexed In Patients With EGFR Exon 21 L858R-Mutant NSCLC
Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile.PFS benefit deepens with treatment duration:
06-02 20:19
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 635.6% to $2.0...
05-18 20:05
